Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

BIGGE

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|February 3, 2006
Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligandsRaymond A Hudack, Nancy S Barta, Chuangxing Guo, et al.
European Journal of Human Genetics : EJHG|July 11, 2025
Implications of monogenic bicuspid aortic valve (BAV) forms among sporadic BAV patientsChristopher M H Bruenger, Frank Oeffner, Laura L Koebbe, et al.
BMC Research Notes|July 2, 2025
Assessing the suitability of formalin-fixed paraffin-embedded (FFPE) tissue for genome-wide association studies (GWAS)Julian Reingruber, Maximilian J Krämer, Jessica Bigge, et al.
Journal of Medicinal Chemistry|July 8, 1999
Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidinesJ L Wright, T F Gregory, C F Bigge, et al.
Journal of Medicinal Chemistry|July 30, 1999
4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonistZ L Zhou, S X Cai, E R Whittemore, et al.
Bioorganic & Medicinal Chemistry|April 9, 2008
Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studiesAgustin Casimiro-Garcia, Christopher F Bigge, Jo Ann Davis, et al.
Journal of Medicinal Chemistry|May 12, 2011
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γAgustin Casimiro-Garcia, Gary F Filzen, Declan Flynn, et al.
Bioorganic & Medicinal Chemistry|February 24, 2009
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of actionChad A Van Huis, Agustin Casimiro-Garcia, Christopher F Bigge, et al.
Cancers|July 12, 2025
Clinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort StudyJan Carl Bigge, Stephanie Bendrich, Hannes Treiber, et al.
Chemical Biology & Drug Design|June 22, 2007
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitorsChad A Van Huis, Christopher F Bigge, Agustin Casimiro-Garcia, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|February 3, 2006
Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligandsRaymond A Hudack, Nancy S Barta, Chuangxing Guo, et al.
European Journal of Human Genetics : EJHG|July 11, 2025
Implications of monogenic bicuspid aortic valve (BAV) forms among sporadic BAV patientsChristopher M H Bruenger, Frank Oeffner, Laura L Koebbe, et al.
BMC Research Notes|July 2, 2025
Assessing the suitability of formalin-fixed paraffin-embedded (FFPE) tissue for genome-wide association studies (GWAS)Julian Reingruber, Maximilian J Krämer, Jessica Bigge, et al.
Journal of Medicinal Chemistry|July 8, 1999
Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidinesJ L Wright, T F Gregory, C F Bigge, et al.
Journal of Medicinal Chemistry|July 30, 1999
4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonistZ L Zhou, S X Cai, E R Whittemore, et al.
Bioorganic & Medicinal Chemistry|April 9, 2008
Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studiesAgustin Casimiro-Garcia, Christopher F Bigge, Jo Ann Davis, et al.
Journal of Medicinal Chemistry|May 12, 2011
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γAgustin Casimiro-Garcia, Gary F Filzen, Declan Flynn, et al.
Bioorganic & Medicinal Chemistry|February 24, 2009
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of actionChad A Van Huis, Agustin Casimiro-Garcia, Christopher F Bigge, et al.
Cancers|July 12, 2025
Clinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort StudyJan Carl Bigge, Stephanie Bendrich, Hannes Treiber, et al.
Chemical Biology & Drug Design|June 22, 2007
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitorsChad A Van Huis, Christopher F Bigge, Agustin Casimiro-Garcia, et al.
Pageof 9